Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 3:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2065–2088 of 4,245 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Study Product Clear all

Conditions: Dry Eye Disease (DED)
Interventions: Active Comparator EBI-005, Placebo Comparator; Drug
Lead sponsor: Eleven Biotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 670 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 45
States / cities: Chandler, Arizona • Mesa, Arizona • Little Rock, Arkansas + 38 more

Conditions: Healthy
Interventions: TD-5202, Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: COVID-19 Disease
Interventions: LAU-7b, Placebo oral capsule; Drug
Lead sponsor: Laurent Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 23
States / cities: Chandler, Arizona • Newport Beach, California • Sacramento, California + 19 more

Conditions: Neoplasms, Medication Toxicity, Tolerance
Interventions: AMXT 1501, Placebo Oral Tablet; Drug
Lead sponsor: Aminex Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Atherosclerotic Cardiovascular Disease
Interventions: Inclisiran; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 30 Years to 50 Years
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 1
States / cities: New York, New York

Conditions: Scleroderma, Systemic Sclerosis, Diffuse Scleroderma, Diffuse Systemic Sclerosis
Interventions: Rilonacept, Placebo; Drug · Other
Lead sponsor: Boston University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bipolar Disorder
Interventions: Aspirin, N-acetyl-cysteine (NAC), Sugar Pill; Drug · Dietary Supplement
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Malaria, Lymphatic Filariasis
Interventions: Ivermectin, Albendazole; Drug
Lead sponsor: Colorado State University; Other
Eligibility: Not listed
Enrollment: 2,712 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: HOCM, Hypertrophic Obstructive Cardiomyopathy
Interventions: Mavacamten, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 21
States / cities: Los Angeles, California • Stanford, California • New Haven, Connecticut + 16 more

Conditions: PARKINSON DISEASE (Disorder), Advanced Parkinson's Disease
Interventions: SER-252 (PEOZ-apomorphine), enFuse; Drug · Device
Lead sponsor: Serina Therapeutics; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Englewood, Colorado • Hallandale, Florida • Maitland, Florida + 1 more

Conditions: Abdominoplasty
Interventions: HEMOBLAST Bellows; Device
Lead sponsor: Biom'Up France SAS; Industry
Eligibility: Not listed
Timeline: 2018
U.S. locations: 1
States / cities: Huntsville, North Carolina

Conditions: Cystic Fibrosis
Interventions: VX-445/TEZ/IVA, TEZ/IVA, IVA, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 28
States / cities: Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 24 more

Conditions: Fontan Palliation
Interventions: Tadalafil, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy
Interventions: Ciraparantag, Placebo, Point-of-Care Coagulometer (investigational device); Drug · Device
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: South Miami, Florida • Secaucus, New Jersey • San Antonio, Texas

Conditions: Allergic Asthma, Atopic Dermatitis, Allergic Rhinitis, Healthy Volunteers
Interventions: Placebo, Omalizumab, MEDI4212 5 mg Subcutaneous, MEDI4212 15 mg Subcutaneous, MEDI4212 60 mg Subcutaneous, MEDI4212 150 mg Subcutaneous, MEDI4212 300 mg Subcutaneous, MEDI4212 300 mg Intravenous; Other · Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 295 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 7
States / cities: Cypress, California • Glendale, California • Denver, Colorado + 4 more

Conditions: Cystic Fibrosis
Interventions: VX-121, TEZ, VX-561, TEZ/IVA, IVA, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 12
States / cities: Los Angeles, California • Oakland, California • Lexington, Kentucky + 9 more

Conditions: Rheumatoid Arthritis (RA)
Interventions: Non-invasive ultrasound stimulation of the spleen - Treatment Setting 1, Non-invasive ultrasound stimulation of the spleen - Treatment Setting 2, Sham ultrasound stimulation (control), Conventional Synthetic DMARD; Device · Drug
Lead sponsor: SecondWave Systems Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Glendale, Arizona • Covina, California • Temecula, California + 2 more

Conditions: Alcohol and Substance-Related Mental Disorders
Interventions: SBIRT, Treatment as usual; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 15 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Castration Resistant Prostate Cancer
Interventions: Rinzimetostat, Darolutamide, Enzalutamide, Docetaxel; Drug
Lead sponsor: ORIC Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 14
States / cities: Glendale, California • Coral Springs, Florida • Jeffersonville, Indiana + 11 more

Conditions: Overweight or Obesity
Interventions: REGN20934, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Glendale, California

Conditions: Barrett's Esophagus, Obesity
Interventions: Omega-3 polyunsaturated fatty acids, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Chronic Oral Food Refusal
Interventions: Amitriptyline, Placebo, Megestrol; Drug
Lead sponsor: Ann Davis, PhD, MPH, ABPP; Other
Eligibility: 9 Months to 8 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 3
States / cities: Kansas City, Kansas • New Orleans, Louisiana • Columbus, Ohio

Conditions: Long COVID, PASC Post Acute Sequelae of COVID 19
Interventions: Valacyclovir celecoxib dose 1, Valacyclovir celecoxib dose 2, Placebo; Drug
Lead sponsor: Bateman Horne Center; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Paroxysmal Nocturnal Hemoglobinuria
Interventions: Crovalimab, Eculizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 2 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Charlotte, North Carolina • Columbus, Ohio

Search by objective public record fields.

Phase 3 Study of EBI-005 in Dry Eye Disease

Single and Multiple Ascending Dose, First-in- Human Study in Healthy Subjects

Study of LAU-7b for the Treatment of Coronavirus Disease 2019 (COVID-19) Disease in Adults

Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers

The Prevent Coronary Artery Disease Trial

IL1-TRAP, Rilonacept, in Systemic Sclerosis

N-Acetyl Cysteine and Aspirin as an Adjunctive Treatment for Bipolar Disorder

Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study

A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy

SAD Study in Patients With Parkinson's Disease and Motor Fluctuations

Registry Study for the Use of HEMOBLAST™ Bellows in Abdominoplasty

A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)

Study of Tadalafil vs. Placebo for Improving Hemodynamics and End-Organ Dysfunction in Fontan Physiology

Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults

A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL

A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis

At-home Ultrasound Localized Therapy for Rheumatoid Arthritis Study [At-home ULTRA Study]

Effectiveness of an Evidence-based Stepped Care System for Alcohol and Other Drug Use Problems Among Congolese Refugees in Zambia

A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity

Modulation of Esophageal Inflammation in Barrett's Esophagus by Omega-3 Fatty Acids

Trial of Amitriptyline for Chronic Oral Food Refusal in Children 9 Months to 8 Years of Age

Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors